October 31st 2023
The application is based on results from the phase 3 CheckMate-901 trial.
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
View More
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
View More
New York GU 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Register Now!
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Adjuvant pembrolizumab improves DFS in certain patients with urothelial carcinoma
October 5th 2023Treatment with adjuvant pembrolizumab reduced the risk of disease recurrence or death versus observation in patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma.
Enfortumab vedotin plus pembrolizumab improves survival in frontline urothelial cancer
September 22nd 2023The EV-302 trial is the confirmatory trial for the FDA’s accelerated approval of pembrolizumab plus enfortumab vedotin for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.
Durvalumab shows promise as perioperative addition for muscle-invasive urothelial carcinoma
September 5th 2023Adding perioperative durvalumab to standard care for patients with resectable muscle-invasive urothelial carcinoma demonstrated promising event-free and overall survival rates in a phase 2 trial.
Dr. Prasad shares the take-home message from the ATLAS study of UGN-102 in LG-IR NMIBC
August 18th 2023“I can tell you from a patient standpoint, I think we all agreed across the panel, there's going to be tremendous enthusiasm from patients about a nonsurgical option,” says Sandip M. Prasad, MD, MPhil.
UGN-102 linked with reduced risk of recurrence, progression, or death in LG-IR NMIBC
August 16th 2023“I think it's a very novel finding, and something completely new to urologic oncology, that a nonsurgical ablative option inside the body can actually make tumors go away,” says Sandip M. Prasad, MD, MPhil.
UGN-102 improves on current standard in low-grade intermediate-risk NMIBC
August 8th 2023The mitomycin-containing reverse thermal gel UGN-102 with or without TURBT reduced the risk of recurrence, progression, or death vs TURBT alone in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.
Dr. Emamekhoo on how his institute is addressing the cancer drug shortage
July 19th 2023“One of the things we do is communicate with our teams and help them with some guidance about how to make decisions about which patients can potentially be treated with alternative approaches,” says Hamid Emamekhoo, MD.